Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/occmed/kqae122 | DOI Listing |
Occup Med (Lond)
January 2025
103 Ave, Queens, New York 10903, USA.
Ann Epidemiol
January 2025
Department of Epidemiology, University of California, Los Angeles Fielding School of Public Health, CA, USA. Electronic address:
Purpose: Harmonizing variables for constructs measured differently across studies is essential for comparing, combining, and generalizing results. We developed and fielded a brief survey to harmonize Likert and continuous versions of measures for two constructs, self-rated health and self-rated memory, for use in studies of French older adults.
Methods: We recruited 300 participants from a French memory clinic in 2023 to answer both the Likert and continuous versions of self-rated health and self-rated memory questions.
Schizophr Res
January 2025
AP-HP, Hôpitaux Universitaires "H. Mondor", DMU IMPACT, INSERM, IMRB, translational Neuropsychiatry, Fondation FondaMental, Univ Paris-Est-Créteil (UPEC), Créteil, France.
Imeta
December 2024
Genome Analysis Laboratory of the Ministry of Agriculture and Rural Affairs, Agricultural Genomics Institute at Shenzhen Chinese Academy of Agricultural Sciences Shenzhen China.
The Conference 2024 provides a platform to promote the development of an innovative scientific research ecosystem for microbiome and One Health. The four key components - Technology, Research (Biology), Academic journals, and Social media - form a synergistic ecosystem. Advanced technologies drive biological research, which generates novel insights that are disseminated through academic journals.
View Article and Find Full Text PDFEBioMedicine
January 2025
Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Section for Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway. Electronic address:
Background: The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated participants who had received baricitinib. This sub-study aimed to investigate whether vaccination influences the safety profile of baricitinib in patients with severe COVID-19.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!